Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer
Joaquim Bosch-Barrera (a) , Alberto Montero (b), José María López-Picazo [SP] (a), Jesús García-Foncillas (a), Marta Ferrer (c), José Ramón Yuste [SP] (b), Ignacio Gil-Bazo (a)
(a) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
(b) Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain
(c) Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, Pamplona, Spain
Magazine: Lung Cancer
Date: Nov 14, 2008Allergology and Immunology Department Infectious Diseases [SP] Medical Oncology
Pemetrexed is a multitargeted antifolate approved for the second-line treatment of locally advanced or metastatic non-small cell lung cancer. The combination of pemetrexed with gemcitabine has been studied in several clinical trials showing a promising antitumor activity with a mild toxicity profile.
We present the case of a patient who experienced fever, arthralgia, skin rash and high serum ferritin levels after first cycle of this chemotherapy combination, compatible with an adult onset Still's disease. This adverse event has not been previously reported.
CITATION Lung Cancer. 2009 Apr;64(1):124-6
you mayBE INTERESTED
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.